Nephrology News

CMS issued a final rule on May 16 that will continue to allow, at least for now, transplant physicians to prescribe most anti-rejection transplant drugs through the Medicare Part D drug formulary.

Researchers found patients who were diagnosed with acute interstitial nephritis had higher levels of urinary TNF-alpha and interleukin-9, which suggests that testing these levels could improve clinical diagnosis, according to a published study.

BOSTON — Kidney transplant recipients from underserved communities have limited access to healthy foods and high levels of stress and anxiety, which contribute to a likelihood of weight gain post-transplant, according to results of a poster presented at the National Kidney Foundation Spring Clinical Meetings.

BOSTON — Revisions to guidelines for vascular access placement in the patient with ESKD – the first in 10 years – place a greater emphasis on matching patients’ care plans and modality options with the access choice.

The use of stress testing in patients waiting for renal transplants varied significantly across transplant centers despite the frequent occurrence of ischemic heart disease in patients with end stage renal disease, according to a study published in JAMA Internal Medicine.

A new HHS report estimates that Medicare would save $73 million during the course of 10 years if Congress extends coverage of immunosuppressive drugs beyond the current 3 years post-transplant.

BOSTON — At the National Kidney Foundation Spring Clinical Meetings, Tracy Mayne, PhD, vice president of medical affairs at Angion Biomedica, spoke about the mechanism of action for ANG-3777 and its phase 3 trial.

BOSTON — Disparities in which women are more likely to develop pregnancy-related AKI, often thought of in terms of genetics and race, may instead be primarily due to socioeconomic factors that result in unequal access to health care, according to a poster presented at the National Kidney Foundation Spring Clinical Meetings.

BOSTON — A supervised exercise training program can be an option for older sedentary adults with CKD stage 3b-4, with adherence comparable to long-term exercise programs of healthier older adults, according to study results presented at the National Kidney Foundation Spring Clinical Meetings.

BOSTON — Combining spironolactone therapy with patiromer may allow patients with CKD and resistant hypertension to safely manage their blood pressure without increasing their risk for developing hyperkalemia, according to phase 2 results from the AMBER trial, presented at the National Kidney Foundation Spring Clinical Meetings.